# LITESPARK-005 (NCT04195750)

> A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)

No report yet. It can be ordered.

- Drugs tested: belzutifan

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04195750
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: Carcinoma, Renal Cell
- Interventions: Belzutifan; Everolimus
- Enrollment: 755
- Primary outcome: Progression-free Survival (PFS) Per Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)
- Primary outcome: Overall Survival (OS)

## Indexed commentary on LITESPARK-005 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 106
- Podcasts: 25
- YouTube: 23
- X videos: 2

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=litespark-005-nct04195750

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04195750", "email": "<work email>"}; the inbox owner confirms by the emailed link.